Charles Swanton
Molecular Biology · 2012–2021
A researcher in the Science corpus: 27 papers; trusts 22 researchers and is trusted by 6 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 355 citations into it; #5,867 of 17,773 by trust here, #2,038 by citations
- Cancer Research — 323 citations into it; #409 of 1,780 by trust here, #89 by citations
- Oncology — 294 citations into it; #479 of 1,698 by trust here, #251 by citations
- Genetics — 157 citations into it
- Immunology — 103 citations into it
- Radiology, Nuclear Medicine and Imaging — 66 citations into it
- Cell Biology — 37 citations into it
- Artificial Intelligence — 36 citations into it
Whom Charles Swanton trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Nicholas McGranahan
- J. Salk
- Ludmil B. Alexandrov
- Sohrab P. Shah
- S. Nik-Zainal
- Ronglai Shen
- D. Haber
- Li Ding
- Robert James Gillies
- Scott L. Carter
Who trusts Charles Swanton overall
Papers from Charles Swanton's perspective
Ordered by how strongly the researchers Charles Swanton trusts endorse each paper. Same corpus, a different order for every researcher.
- Tumour evolution inferred by single-cell sequencing (Nature)
- The DNA damage response and cancer therapy (Nature)
- Genetic variegation of clonal architecture and propagating cells in leukaemia (Nature)
- A small cell lung cancer genome reports complex tobacco exposure signatures (Nature)
- Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution (Nature)
- Genomic landscape of non-small-cell lung cancer in smokers and never-smokers (Thorax)
- An APOBEC Cytidine Deaminase Mutagenesis Pattern is Widespread in Human Cancers (Nature Genetics)
- Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft (Nature)
- Clonal evolution in cancer
- Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells (Nature Medicine)
Their papers
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution (2015) — 630 citations
- The causes and consequences of genetic heterogeneity in cancer evolution (2013) — 2,128 citations
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing (2014) — 1,192 citations
- Spatial and temporal diversity in genomic instability processes defines lung cancer evolution (2014) — 1,056 citations
- Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. (2017) — 2,488 citations
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal (2018) — 734 citations
- Renal cell carcinoma (2017) — 1,839 citations
- deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution (2016) — 1,016 citations
- Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. (2015) — 1,041 citations
- Toward understanding and exploiting tumor heterogeneity (2015) — 708 citations
- Chromosomal instability drives metastasis through a cytosolic DNA response (2018) — 1,367 citations
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA (2020) — 1,145 citations
- Intratumor heterogeneity: evolution through space and time. (2012) — 909 citations
- Replication stress links structural and numerical cancer chromosomal instability (2013) — 840 citations
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. (2021) — 805 citations
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition (2021) — 716 citations
- Preexisting and de novo humoral immunity to SARS-CoV-2 in humans (2020) — 900 citations
- Artificial intelligence in Cancer Imaging: Clinical Challenges and Applications (2019) — 1,608 citations
- Neoantigen directed immune escape in lung cancer evolution (2019) — 783 citations
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018) — 704 citations